On April 30, 2025, Matinas BioPharma amended its bylaws to lower the quorum requirement for stockholder meetings to one-third of voting shares, enhancing meeting feasibility. Additionally, it approved cash retention bonuses for executives Jerome Jabbour ($299,000) and Keith Kucinski ($166,400) in case of a change in control before March 31, 2026.